Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy

NCT03982121 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Study never began because of withdrawal of the industrial partner

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG: FOLFOX regimen
DRUG: Nivolumab
DRUG: Ipilimumab
DRUG: GLA-SE

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris